Healthcare Industry Insights: July 2019

Wednesday 31 July 2019

Population Health Management Market: Global Industry Analysis, Trends and Segment Forecast, 2025

The global Population Health Management Market size is expected to reach USD 101.0 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 20.7% during the forecast period. The need for population health services that combine multiple functionalities is increasing, due to the complex nature of care delivery and payment models. PHM solutions can process clinical, financial, and operational data for the improvement of efficiency and patient care. The convenience offered by value-based payment models instead of Fee-for-Service (FFS) is responsible for increased adoption of these solutions by the Accountable Care Organizations (ACOs).

ACOs, consist of hospitals, clinics, doctors, and other caregivers, collaborate with payers for the delivery of high-quality patient care. Private and public insurance providers have introduced various disease management programs, to assist in the treatment of chronic illnesses. These multidisciplinary efforts are expected to result in effective treatment outcomes and are likely to suggest best suitable courses of action that need to be undertaken. Successful large-scale trials in U.S. have enabled significant advancements in disease management programs.

The market has a healthy mix of vendors offering PHM along with other healthcare IT solutions. Acquisitions and partnerships are the major strategies adopted by the companies operating in the population health management market. For instance, in 2018 Allscripts announced completion of acquisition of the HealthGrid Holding Company, a developer of enterprise patient engagement solution. The acquisition signifies expansion of the Allscripts FollowMyHealth platform that provides patient engagement solutions focused on connecting consumers with providers.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/population-health-management-phm-market

Further key findings from the report suggest:

Based on the products, the services segment held majority of the market share in 2018, as healthcare providers prefer in-house maintenance services
In 2018, healthcare provider held the largest market share of the end-use segment. The providers can focus effectively on patient-centric care and reducing overall costs
North America was the largest regional market in 2018 and is likely to retain its position over the forecast period, as the providers, payers, providers-payers, and accountable care organizations promote the use of PHM services
Asia Pacific is expected to witness the fastest growth in the forthcoming years due to rising healthcare expenditure and improving healthcare infrastructure
Allscripts, McKesson Corporation, and Cerner Corporation among others are some of the key players operating in the Population Health Management (PHM) market. Business partnerships and acquisitions are some of the key strategic initiatives undertaken by these companies to strengthen their market presence.

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/

Tuesday 30 July 2019

3D Cell Culture Market Size, Share & Trends Analysis Report, 2024

The global 3D Cell Culture Market size is expected to reach USD 1.69 billion by 2024, according to a new report by Grand View Research, Inc., exhibiting a 14.8% CAGR during the forecast period. Need to incorporate 3D cell culture systems in research for better representation of in vivo environment has driven development of new materials and methods, thereby propelling market growth.

3D cell culture is more suitable for in vivo modeling due to the resemblance they provide to morphology of organ or cells. Several 3D cell culture options are available in the form of scaffold-based, scaffold-free, and 3D bioreactor systems. Emergence of 3D optimized assays, kits, and protocols, along with maturity in development of different assay techniques, is projected to accelerate market growth.

Increasing adoption of tissue engineering and organ transplantation for chronic diseases is projected to drive adoption in research over the forecast period. Furthermore, use of microchips to implement culturing through use of micro-fabricated tissue component is expected to present the market with potential avenues.

Fabrication techniques to produce scaffold-free systems that are inexpensive, transparent, and compatible with liquid handling tools have emerged. Rapid adoption of these systems for tissue engineering research, drug discovery, and personalized medicine contributes to market growth. Scaffold-free technology is expected to observe the fastest growth over the next few years, registering an estimated CAGR of around 15.7% from 2016 to 2024.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/3d-cell-culture-market

Further key findings from the report suggest:

Emergence of novel fabrication techniques contributes to the growth of scaffold-free 3D cell culture systems
Rapid adoption of culturing systems in cancer research for development of immortalized established cell lines or primary cell cultures to perform in vivo drug screening has led to its largest revenue share
3D bioprinting enables creation of 3D printed building blocks of embryonic stem cells, which could be further used for micro-organ generation and tissue regeneration experiments
Changing of regulatory policies for stem cell research and high potential of 3D culturing tools fuels the stem cell research segment
North America dominated the global 3D cell culture market with a share of over 41.0% in 2016. Presence of major pharma and biotech players that collaborate with research laboratories to implement these technologies drives progress in U.S.
Asia Pacific is projected to witness substantial growth over the forecast period owing to rapid developments across major economies, especially in the tissue engineering and stem cell research domain. APAC is expected to exhibit a CAGR of 16% during the forecast period
Key players include Merck, 3D Biotek LLC; 3D Biomatrix; Nano3D Biosciences Corning Inc.; VWR International, LLC; Thermo Fisher Scientific; Global Cell Solutions, Inc.; Becton Dickinson and Company; Tecan; InSphero AG; and Lonza Group
Major players focus on collaborating with laboratories to commercialize technologies that are not potentially established in the market space.

Veterinary Chemistry Analyzer Market is Driven by Rising Animal Healthcare Expenditure and Increasing Pet Ownership

The global Veterinary Chemistry Analyzers Market size is expected to reach USD 1.3 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 8.2% during the forecast period. Rising animal healthcare expenditure and increasing pet ownership are some of the major factors contributing to the growth of the market.

Increasing incidence of zoonotic diseases is one of the key trends escalating market growth. According to an article published in the Centers for Disease Control and Prevention (CDC) in 2017, scientists estimated that 3 out of every 4 emerging infectious diseases in people are transmitted through animals, and more than 6 out of every 10 known infectious diseases in people are transmitted through animals.

Increasing demand for animal proteins is leading to a global rise in livestock production and increase in exports of animal products. Rising disposable income and changing lifestyles are stirring up the demand for animal-derived food products.

According to the American Pet Products Association (APPA), the U.S. pet food sales doubled to USD 22 billion from 2000 to 2014 and are expected to rise at a CAGR of 2.5%. According to Mintel, in 2014, 79.0% of the U.S. pet owners considered the quality of pet food products is as important as their own.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/veterinary-chemistry-analyzer-market

Further key findings from the report suggest:

Benchtop analyzers were the largest segment, based on type, in 2016 due to their accuracy and precision. Portable analyzers are anticipated to witness remarkable growth owing to surging demand for shorter analysis time and quicker results
The consumables segment was the largest as well as the fastest growing segment during the forecast period due to the ability of consumables to create a standardized workflow and advancements such as ready-to-use liquid reagents
Blood chemistry dominated the application segment owing to increasing number of veterinary practitioners globally
The hospitals segment held the largest market share in 2016 and is expected to exhibit a noteworthy CAGR over the forecast period due to increasing demand for in-house analyzers
North America accounted for approximately 40.0% of the market in 2016, owing to increasing incidence of zoonotic diseases and growing demand for pet insurance
Asia Pacific is anticipated to witness healthy growth over the next decade due to increasing pet ownership in countries such as India and China. It is expected to rise at a CAGR of 9.4% over the forecast period
Key players including IDEXX Laboratories, Inc.; Abaxis; URIT Medical; Randox Laboratories Ltd.; Heska Corporation; and Eurolyser Diagnostica GmbH dominated the veterinary chemistry analyzers market in 2016.

Anti-acne Cosmetics Market Trends, Applications, Segmentations and Future Scope, 2019-2026

The global Anti-Acne Cosmetics Market size is expected to reach USD 3.88 billion by 2026 according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 8.2% during the forecast period. The high psychological burden associated with acne is mainly expected to drive the anti-acne cosmetics market. Moreover, easy availability of anti-acne products through several offline and online shops is also anticipated to drive the growth.

According to the America Academy of Dermatology, acne is one of the common skin disorders in U.S., affecting approximately 50 million individuals every year with nearly 85% individuals between the age group of 12 to 24 years suffering from minor acne. Thus, such high prevalence among adolescents and young adults is anticipated to fuel the market growth.

According to a study conducted by SkinStore, an average American women uses nearly 16 skin care products on her face daily and spends approximately USD 8 every day on facial cosmetics products to prevent acne, pigmentation, blemishes, dark circles, and wrinkles. Such beauty regimes are anticipated to propel the market growth.

According to a study by the University of Limerick, negative social stigma associated with acne reduces the quality of life of individuals, increases their psychological distress, and causes physical problems such as headaches, sleep disturbance, and gastrointestinal issues. Hence, the negative perceptions associated with acne is anticipated to increase the demand for anti-acne cosmetics.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/anti-acne-cosmetics-market

Further key findings from the report suggest:

Creams and lotions segment led the market in 2018 as acne cream is the first line of therapy for all types of acne and it also provides skin moisturization, thus reducing skin dryness caused by acne
The others segment is expected to expand at a rapid pace over the forecast period, due to the compatibility of these products with various skin types and their lightness on skin as compared to creams and lotions
Women segment held the dominant market share in 2018 and is expected to grow at a remunerative rate during the forecast period owing to high prevalence and awareness regarding the same
Asia Pacific is anticipated to grow significantly over the forecast period due to increasing disposable income in developing countries as well as increasing population leading an unhealthy lifestyle
Some of the key players in the anti-acne cosmetics market are Neutrogena; Clinique; Murad; Kose; LaRochPosay; Mentholatum; L'Oréal; Proactiv; and Vichy

Monday 29 July 2019

mHealth Applications Market Trends, Growth, Analysis and Future Scope, 2025

The Global mHealth Apps Market size is expected to reach USD 236.0 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 44.7% during the forecast period. The market is majorly driven by increasing adoption of advanced technologies in healthcare facilities and the need to reduce long waiting periods to access healthcare facilities from specialists.Availability of mobile applications for users is witnessing a rapid growth, especially healthcare apps that assist consumers in self-management of disease, wellness, and chronic conditions. This increased role of patients coupled with the rising importance in staying updated and informed about their own healthcare decisions, contributing to the rise in adoption of mHealth apps globally.

Healthcare industry has been transitioning towards a value-based care model with mHealth becoming a widespread trend owing to the advent of technologies such as remote monitoring, electronic medical record, and other communication platforms. The increasing prevalence of disorders, such as diabetes, hypertension, cancer, and obesity along with the growing awareness about wellness and other preventive measures diseases among patients is expected to boost the mHealth market growth.

mHealth leverages from the 4Ps: personalized, predictive, participatory, and preventive measures for care delivery to provide optimal care to users. Moreover, rising penetration of smartphones, and other electronic devices, especially, in low- and middle-income countries and increasing focus on the use of mobile technology to manage care delivery is anticipated to benefit the market.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/mhealth-app-market

Further key findings from the report suggest:

Rapid growth in chronic diseases along with the rise in the number of app users is accountable for the mHealth apps market growth
The types of mHealth apps include fitness, lifestyle management, nutrition and diet, women’s health, medication adherence, healthcare providers, and disease management. Of these, the fitness category accounted for the majority of segment share in 2018
mHealth app vendors are focusing their attention on women's health, diet, and medication reminders. According to Wired, a mobile advertising and analytics platform, women are more inclined toward tracking their health than men
Physicians are increasingly recommending the use of mHealth apps to their patients, which is likely to increase the adoption rate of mHealth apps
North America led the mhealth applications market in 2018 in terms of revenue share pertaining to the technological advancements and presence of major players in the region
Some of the key players are Johnson & Johnson; Abbott Laboratories; AstraZeneca; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; Novartis AG; GlaxoSmithKline plc; Merck and Co., Inc.; Pfizer; and Sanofi

Sunday 28 July 2019

Antibiotic Resistance Market 2018: Industry Analysis & Outlook to 2025

The global Antibiotic Resistance Market size is estimated to reach USD 12.07 billion by 2025. According to a new report by Grand View Research, Inc., it is anticipated to post a CAGR of 5.6% during the forecast period. Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market.

Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don’t find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance.

Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.

Browse Details of Report @

https://www.grandviewresearch.com/industry-analysis/antibiotic-resistance-market

Further key findings from the report suggest:

In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.

Friday 26 July 2019

Mouth Ulcers Treatment Market to Register CAGR of 3.8% till 2026

The global Mouth Ulcers Treatment Market size is projected to reach USD 1.32 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 3.8% during the forecast period. Increasing geriatric population and rising awareness towards oral hygiene are among the key trends stimulating market growth.

Growing global geriatric population is poised to trigger the number of cases of mouth ulcers. As per the findings of the United Nations Organization (UNO), population base of age 60 years or older across the globe was 962.0 million in 2017, which was more than twice as large as in 1980, when the population was 382.0 million. With upswing in the demand for denture fittings in this population, rise in the incidences of improper fittings and deficiency of vitamin B & folic acid is anticipated. Such incidents can lead to mouth ulcers.

Newly fitted dentures takes some time to adjust. During the procedure, inner area of the mouth remains moist for a certain period. Such conditions favor fungal infection leading to ulcer. Older population often suffer from such conditions, due to which they are prone to oral problems. In addition, deficiency of vitamins is a common phenomenon observed among geriatric population, which also increases the probability of suffering from mouth ulcer.

Rising awareness regarding oral hygiene in developing countries is also estimated to drive the market over the forecast period. Campaigns on oral hygiene in rural areas of developing countries are working in favor of the market. For instance, every year, Colgate-Palmolive Company conducts an oral health month in rural areas of India in order to impart awareness regarding oral hygiene. Such initiatives are expected to encourage people to take up necessary treatments. Furthermore, rise in tobacco usage in countries such as U.K. and Mexico is projected to boost the rate of mouth ulcers, thereby benefitting the growth of the market.

Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/mouth-ulcers-treatment-market

Further key findings from the report suggest:

Analgesics and Corticosteroids are poised to exhibit the highest CAGR during the forecast period. These are the most prescribed drugs by doctors and are easily available
By 2026, Asia Pacific is likely to dominate the mouth ulcer treatment market with a share of around 63.0%. Increasing awareness pertaining to oral hygiene and treatment and rising prevalence of aphthous ulcers are likely to supplement the growth of the market
Some of the key companies present in the market are Blistix Inc., Church & Dwight Co., Inc., 3M, Colgate-Palmolive Company, Pfizer, Bristol-Myers Squibb (BMS), and others are expected to dominate the market over the forecast period.

Healthcare IT Market - Enhanced Healthcare Facilities and Technological Advancement

The global Healthcare IT Market is anticipated to reach USD 104.5 billion by 2020, according to a new report by Grand View Research, Inc. Increasing demand for enhanced healthcare facilities and introduction of technologically advanced systems are expected to boost industry growth.

Increasing geriatric population prone to chronic diseases resulting into high patient base is triggering the demand for sophisticated healthcare facilities. Furthermore, increasing number of patients requiring home healthcare acts as an effective growth driver for this market.

According to a report published by the U.S. Centers for Disease Control and Prevention (CDC) in 2011, the number of patients needing home healthcare was nearly 4.7 million in the U.S. and is on a constant rise, which is further expected to fuel the healthcare IT market demand.

Advent of technologically advanced software, such as interoperable system and cloud computing, is expected to attract more investors focus on developing integrated healthcare system to curb problems associated with conventional procedures of record keeping. For example, the uses of e-healthcare record system to maintain patient database help to provide instant information about patients’ health in case of emergency.

Telecommunication and telehealth accounted for over 40.0% of the market share owing to the high usage rates in 2013. Introduction of technological advancements such as Teleimmersive Environment for Everybody (TEEVE) and Session Initiation Protocol (SIP) are the factors promoting this segment’s growth.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/healthcare-it-market

Electronic Health Records (EHR) is expected to register an upward shift to reach up to USD 26.72 billion in 2020. Growth is primarily driven by the rising demand for integrated information system in the field of healthcare IT. Faster accessibility and low maintenance cost are the two most significant factors contributing towards the rising demand of these EHR systems.

In 2013, North America market was valued at around USD 20.0 billion owing to the factors such as favorable government initiatives pertaining to the introduction of technologically advanced healthcare IT facilities, sophisticated healthcare infrastructure, and increasing patient awareness levels coupled with relatively higher healthcare expenditures in the region.

On the other hand, Asia Pacific healthcare IT market is expected to reach at over USD 19.6 billion by registering lucrative growth rate in 2020. Growth is attributed to the rising healthcare expenditure, larger untapped opportunities, and growing disposable income level.

Prominent players operating in this industry include Athenahealth Inc., GE Healthcare, Agfa Healthcare, Philips Healthcare, E-MDS Inc., Carestream Health McKesson Corporation, Carestream Health eClinicalworks, and Hewlett-Packard.

Thursday 25 July 2019

Precision Medicine Market is Estimated to Value $85.5 Billion by 2025

The global Precision Medicine (Diagnostics/Therapeutics) Market size is expected to reach USD 85.5 billion by 2025 at a 9.9% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Trends such as introduction of cost-effective genomic and molecular biology testing methods, increasing prevalence of cancer and rare diseases, and rising use of big data in precision medicine are some of the key factors boosting market growth.

The Human Genome Project introduced some marvelous cutting-edge techniques such as whole genome sequencing and targeted sequencing. These technologies are being used by researchers for the study of genomes and creation of personalized therapies for treatment of various illnesses. Today, the prevalence of diseases in areas such as oncology, immunology, and neurology has rapidly increased across the globe.

Researchers, healthcare professionals, and big pharma and biotech companies are working together to recognize new focused treatments options for the wellbeing of patients. Currently, there are many therapies and drugs under clinical trials for treatment of different types of cancers. Moreover, researchers have also shown an inclination toward development of precision medicines and diagnostics in non-oncologic disease areas.

Apart from therapeutics, the diagnostics field has also witnessed rapid growth in the past few years. The use of next generation sequencing (NGS), biomarkers, companion diagnostics, and esoteric tests can possibly change and affect prescription patterns of pharmaceutical medicines. Personalized medicines have very high chances of becoming a massive success in the next 20 years and have the capacity to treat and cure a few obstinate illnesses, which was not possible before.

Involvement of government and regulatory bodies has played a very important role in the growth of this field. In 2015, the then U.S. government announced the launch of the Precision Medicine Initiative. The following year, China launched the China Precision Medicine Initiative, which is a 15-year project that aims to build the country as a leader in development of precision therapies.

At present, more than 40% of the medications in biotech and pharmaceutical companies’ improvement pipeline incorporate biomarkers. The overview likewise recommended that some biopharmaceutical organizations have collaborated and joint their ventures in the past five years and are expected to continue doing so in the coming years. The diagnostic and therapeutic precision medicine market thus holds immense potential and is quickly turning into a fundamental segment of patient care.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/precision-medicine-diagnostics-therapeutics-market

Further key findings from the report suggest:

Technologies such as gene sequencing, biomarkers, big data analytics, and companion diagnostics are anticipated to drive this market in the coming years
By end use, clinical labs held the dominant share in the market in 2017. The home care testing segment, on the other hand, has been witnessing rapid growth due to its speed, efficiency, and convenience
On the basis of indication area, therapeutic precision medicines for oncology held the largest market share in 2017. However, there has been a change in focus of researchers toward the development of precision medicines for non-oncologic diseases. This has resulted in greater focus on immunological, genetic, and rare diseases
The North America market currently holds the largest share and is expected to grow further during the forecast period. The market is primarily driven by supportive policies and initiatives by the government and strong presence of market players. Asia Pacific is expected to emerge as the fastest growing region in this market
GE Healthcare; Abbott Laboratories; Precision Biologics; Foundation Medicine; Illumina, Inc.; and IBM Watson are some of the prominent players in the precision medicine diagnostics market and precision medicine therapeutics market